RAP-219 Shows Sustained Efficacy in Focal Onset Seizure Trial, Advancing to Phase 3
RAPP has more than doubled off its 52-week low of $7.73.
Summary
Rapport Therapeutics reported strong follow-up results from its Phase 2a trial of RAP-219 for focal onset seizures, showing sustained and enhanced seizure reduction post-treatment and an extended half-life, paving the way for Phase 3 trials.
Key Events · Product Development and Regulatory · RAPP
-
Positive Phase 2a Follow-up Results
RAP-219 demonstrated sustained and clinically meaningful reductions in long episodes (LEs) and clinical seizures during the 8-week follow-up period after treatment concluded.
-
Enhanced Seizure Reduction Post-Treatment
In weeks 9-12 (first four weeks of follow-up), RAP-219 showed even greater reductions in LEs (80% median) and clinical seizures (90% median) compared to the initial 8-week treatment period.
-
Extended Drug Half-Life Confirmed
The estimated half-life of RAP-219 has been revised to approximately 22 days (up from 14 days), explaining the sustained therapeutic levels and prolonged efficacy.
-
Advancement to Phase 3 Trials
The company plans to initiate two pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) for RAP-219 in focal onset seizures in the second quarter of 2026.
Analysis · RAPP · Life Sciences
Rapport Therapeutics announced highly positive follow-up results from its Phase 2a trial of RAP-219 in focal onset seizures (FOS). The data demonstrate sustained and even improved seizure reduction during the 8-week follow-up period after treatment ended, which is a significant positive signal for the drug's long-term efficacy. The estimated half-life of RAP-219 has also been extended to approximately 22 days, which supports the sustained therapeutic levels observed. These results strongly de-risk the program and provide a robust foundation for the planned initiation of two pivotal Phase 3 trials in Q2 2026. This update, following a concurrent news release, provides comprehensive details that are critical for investors assessing the company's clinical pipeline and future growth prospects.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RAPP was trading at $36.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $7.73 to $42.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.